Search
Ulcerative Colitis Paid Clinical Trials in Wisconsin
A listing of 7 Ulcerative Colitis clinical trials in Wisconsin actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 7 of 7
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Herpes Clinical Trial
Recruiting
Help move the future of herpes simplex virus type 2 (HSV-2) genital herpes forward by participating in the Vantage Trial for an investigational vaccine.
Conditions:
HSV-2 Infection
HSV-2
Herpes
Herpes Simplex
Genital Herpes
Genital Herpes Simplex Type 2
HSV-2 Genital Herpes
HIV-1 and HSV-2 Coinfection
Featured Trial
Fronto-Temporal Dementia Research Study
Recruiting
The aim of this study is to better understand the genetics of FTD, in order to
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
empower researchers with the data they need to potentially identify treatment
options. Help researchers accelerate their understanding of Frontotemporal
Dementia and get access to free, at-home genetic testing and genetic counseling
before and after your test.
Conditions:
Dementia
Frontotemporal Dementia
Alzheimer Dementia
Dementia Alzheimers
Mild Dementia
Dementia
Alzheimer Type
Alzheimer Disease
Alzheimer's Disease
Dementia of Alzheimer Type
Parkinson's Disease
Parkinson Disease
Idiopathic Parkinson's Disease
ALS
Memory Disorders
Memory Impairment
Memory Loss
Age-Related Memory Disorders
Featured Trial
Clinical Research for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease
Recruiting
The Redwood Study is currently enrolling adults 18 to 75 years of age with Alpha-1
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Liver Disease. The purpose of the study is to evaluate how safe and effective an
investigational study drug is compared to a placebo (both groups will receive
injections, but the placebo contains no active medication) in the treatment of liver
disease. If you or any of your family members have a confirmed or suspected
diagnosis of Alpha-1 Liver Disease, you may be eligible.
Conditions:
Crohn's Disease
COPD
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema or COPD
Alpha 1-Antitrypsin Deficiency
AAT Deficiency
AATD
Chronic Obstructive Pulmonary Disease
Emphysema
Pulmonary Emphysema
Bronchiectasis
Panniculitis
Hepatocellular Carcinoma
Cirrhosis
Liver Cirrhosis
Cirrhosis
Liver
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Non-Alcoholic Fatty Liver Disease
Liver Diseases
Liver Disease
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).
Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/29/2023
Locations: Wisconsin Center for Advanced Research, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled.
All eligible participants will initially receive open label tofacitinib... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
11/21/2023
Locations: Children's Wisconsin, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
10/30/2023
Locations: Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: University of Wisconsin Hospital & Clinics, Madison, Wisconsin
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Recruiting
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/25/2023
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: Advocate Aurora Health - Aurora St. Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Recruiting
The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC and to evaluate the efficacy of cobitolimod maintenance treatment compared to placebo in inducing or maintaining clinical remission at week 52, in participants with clinical response at week 6 after induction treatment with cobitolimod.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2022
Locations: Wisconsin Center For Advanced Research, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
1 - 7 of 7